Skip to main content
. 2012 Feb 29;7(2):e31980. doi: 10.1371/journal.pone.0031980

Table 1. Clinical and demographic characteristics of participants in the Agenda Trial.

Characteristic Escitalopram(n = 41) Placebo(n = 39) All Participants(n = 80)
Age – yr, mean ± SD 32±11 31±11 32±10
Women – N (%) 15 (37) 14 (36) 29 (36)
Education – mean ± SD
Years of school 11±1 11±1 11±1
Years of further education 3±2 3±2 3±2
First degree relatives of patient with a history of major depressive disorder– median (25,75 quartiles) 1 (1;2) 1 (1;2) 1 (1;2)
17-item Hamilton Depression Scale Score – median (quartiles) (range) 1 (0;3)(0–7) 1 (0;3)(0–7) 1 (0;3)(0–7)
Beck Depression Inventory, 21-item, depression – median (25,75 quartiles) 2 (0;4) 2 (0;3) 2 (0;5)
Side Effects UKU total score (4 weeks), median (25,75 quartiles), (range) 1(0–4), (0–13) 0(0–2), (0–7) 0(0–3), (0–13)
Plasma escitalopram (4 weeks), nmol/l, 50±29
- mean ± SD, median (range) 48 (<10–138) <10
Eysenck (entry)- mean ± SD, median (25,75 quartiles)
6.8±5.3 7.3±4.4 7.0±4.8
Neuroticism 7 (1.5;10) 6.0 (4;10) 6.5 (3;10)
16.0±3.8 14.7±4.5 15.4±4.2
Extraversion 17 (14.5; 18.5) 17 (12;18) 17 (14;18)
NEO-PI-R (entry)- mean ± SD, median (25,75 quartiles)
68±24 71±18 70±21
Neuroticism 66 (50;85) 70 (59–85) 68 (55;85)
125±19 123±16 124±18
Extraversion 123 (110;138) 125 (111;136) 123 (110;136)
114±17 118±18 116±74
Openness 114 (99;125) 120 (106;131) 115 (100;130)
124±18 128±12 126±54
Agreeableness 125 (118;136) 128 (119;138) 127 (118;137)
114±20 113±17 114±18
Conscientiousness 115 (104;133) 111 (102;124) 112 (102;126)